The promises and challenges of using gene mutations for patient stratification in follicular lymphoma.
暂无分享,去创建一个
[1] R. Gascoyne,et al. Can histologic transformation of follicular lymphoma be predicted and prevented? , 2017, Blood.
[2] K. Tarte,et al. GENE‐EXPRESSION PROFILING PREDICTS DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA , 2017 .
[3] R. Siebert. JOHN ULTMANN MEMORIAL LECTURE: “GENOMES IN TRANSIT: WHAT MULTI‐OMICS CAN TELL US ON LYMPHOMAS” , 2017 .
[4] L. Xerri,et al. EVALUATION OF CLINICOGENETIC RISK MODELS FOR OUTCOME OF FOLLICULAR LYMPHOMA PATIENTS IN THE PRIMA TRIAL , 2017 .
[5] G. Salles,et al. INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMAS , 2017 .
[6] F. Jardin,et al. BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab , 2017, American journal of hematology.
[7] A. Rosenwald,et al. Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium , 2017, Haematologica.
[8] F. Jardin,et al. EZH2 alterations in follicular lymphoma: biological and clinical correlations , 2017, Blood Cancer Journal.
[9] K. Basso,et al. The CREBBP Acetyltransferase Is a Haploinsufficient Tumor Suppressor in B-cell Lymphoma. , 2017, Cancer discovery.
[10] Christopher A. Miller,et al. Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. , 2017, Blood.
[11] Ash A. Alizadeh,et al. Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice. , 2016, Blood.
[12] A Rosenwald,et al. Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma , 2016, Leukemia.
[13] O. Elemento,et al. CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas. , 2017, Cancer discovery.
[14] M. Ghielmini,et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] L. Gordon,et al. Recommendations for Clinical Trial Development in Follicular Lymphoma , 2017, Journal of the National Cancer Institute.
[16] Ali Bashashati,et al. Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study , 2016, PLoS medicine.
[17] Ash A. Alizadeh,et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA , 2016, Science Translational Medicine.
[18] W. Chan,et al. Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells , 2016, Cell.
[19] Allison P. Heath,et al. Toward a Shared Vision for Cancer Genomic Data. , 2016, The New England journal of medicine.
[20] Ryan D. Morin,et al. Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations. , 2016, Blood.
[21] A. Rosenwald,et al. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. , 2016, Blood.
[22] L. Staudt,et al. Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma. , 2016, Blood.
[23] David T Yang,et al. Follicular lymphoma: evolving therapeutic strategies. , 2016, Blood.
[24] G. Salles,et al. The European Hematology Association Roadmap for European Hematology Research: a consensus document. , 2016, Haematologica.
[25] S. Barrans,et al. Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma , 2015, Nature Genetics.
[26] A. Rosenwald,et al. STAT6 Is Recurrently and Significantly Mutated in Follicular Lymphoma and Enhances the IL-4 Induced Expression of Membrane-Bound and Soluble CD23 , 2015 .
[27] R. Gascoyne,et al. Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells , 2015, Clinical Cancer Research.
[28] Thomas P. Howard,et al. SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2 , 2015, Nature Medicine.
[29] K. Ballman,et al. Biomarker: Predictive or Prognostic? , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] O. Elemento,et al. The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development , 2015, Nature Medicine.
[31] Robert Kridel,et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. , 2015, The Lancet. Oncology.
[32] K. Basso,et al. Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis , 2015, Nature Medicine.
[33] J. Cerhan,et al. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] Roland Schmitz,et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma , 2015, Nature Medicine.
[35] L. Staudt,et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. , 2015, The Lancet. Oncology.
[36] Karin Tarte,et al. CD10 delineates a subset of human IL-4 producing follicular helper T cells involved in the survival of follicular lymphoma B cells. , 2015, Blood.
[37] L. Staudt,et al. A roadmap for discovery and translation in lymphoma. , 2015, Blood.
[38] Karen Cichowski,et al. Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy , 2015, Cell.
[39] K. Basso,et al. Germinal centres and B cell lymphomagenesis , 2015, Nature Reviews Immunology.
[40] Ash A. Alizadeh,et al. Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation , 2015, Proceedings of the National Academy of Sciences.
[41] Benjamin G. Bitler,et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers , 2015, Nature Medicine.
[42] M. Merad,et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups , 2015, The Journal of experimental medicine.
[43] A. K. Church,et al. BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. , 2015, Blood.
[44] M. Kaminski,et al. Activating STAT6 mutations in follicular lymphoma. , 2015, Blood.
[45] Tyler B. Hughes,et al. Enhancer sequence variants and transcription-factor deregulation synergize to construct pathogenic regulatory circuits in B-cell lymphoma. , 2015, Immunity.
[46] L. Staudt,et al. Monitoring of Circulating Tumor DNA As Minimal Residual Disease in Diffuse Large B-Cell Lymphoma , 2014 .
[47] Adrien B. Larsen,et al. Loss of signaling via Gα13 in germinal center B cell-derived lymphoma , 2014, Nature.
[48] Bernd Holleczek,et al. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. , 2014, The Lancet. Oncology.
[49] R. Gascoyne,et al. The tumour microenvironment in B cell lymphomas , 2014, Nature Reviews Cancer.
[50] W. Hiddemann,et al. How we manage follicular lymphoma , 2014, Leukemia.
[51] S. Rodig,et al. The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s Macroglobulinemia , 2014, Leukemia.
[52] M. Merad,et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups , 2014, The Journal of experimental medicine.
[53] M. Kaminski,et al. Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma. , 2014, Blood.
[54] Raul Rabadan,et al. Genetics of follicular lymphoma transformation. , 2014, Cell reports.
[55] M. Calaminici,et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma , 2013, Nature Genetics.
[56] L. Staudt,et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. , 2013, Blood.
[57] Summer S. Han,et al. Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. , 2013, Blood.
[58] M. Calaminici,et al. Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] O. Elemento,et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. , 2013, Cancer cell.
[60] Ash A. Alizadeh,et al. Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. , 2012, Blood.
[61] A. McKenna,et al. Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia , 2012, Cell.
[62] R. Advani,et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] Yan Liu,et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations , 2012, Nature.
[64] D. Weinstock,et al. The evolving contribution of hematopoietic progenitor cells to lymphomagenesis. , 2012, Blood.
[65] K. Tarte,et al. High rate of TNFRSF14 gene alterations related to 1p36 region in de novo follicular lymphoma and impact on prognosis , 2012, Leukemia.
[66] D. Neuberg,et al. Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation. , 2012, Cancer discovery.
[67] Govind Bhagat,et al. Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. , 2011, Cancer cell.
[68] Konstantinos J. Mavrakis,et al. The Eph-Receptor A7 Is a Soluble Tumor Suppressor for Follicular Lymphoma , 2011, Cell.
[69] Steven J. M. Jones,et al. Frequent mutation of histone modifying genes in non-Hodgkin lymphoma , 2011, Nature.
[70] Ryan D. Morin,et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. , 2011, Blood.
[71] Raul Rabadan,et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma , 2010, Nature.
[72] R. Gascoyne,et al. Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis. , 2010, Cancer research.
[73] J. Byrd,et al. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.
[74] Giovanni Martinelli,et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[75] J. Cerhan,et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[76] L. Staudt,et al. The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. , 2008, Blood.
[77] J. Gribben. How I treat indolent lymphoma. , 2007, Blood.
[78] G. Schwarzer,et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. , 2007, Journal of the National Cancer Institute.
[79] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[80] D. Weisenburger,et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. , 2006, Blood.
[81] A. Fukamizu,et al. Acetylation of Foxo1 alters its DNA-binding ability and sensitivity to phosphorylation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[82] Robert Tibshirani,et al. Immune signatures in follicular lymphoma. , 2005, The New England journal of medicine.
[83] L. Staudt,et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. , 2004, The New England journal of medicine.
[84] K. Offit,et al. p53 mutations are associated with histologic transformation of follicular lymphoma. , 1993, Blood.
[85] D. Longo,et al. p53 mutation is associated with progression in follicular lymphomas. , 1993, Blood.
[86] D. Haller,et al. Non-Hodgkin's lymphomas. , 1984, The Medical clinics of North America.